# TRAX (First Tracks Biotherapeutics, Inc.) - SEC EDGAR Financial Statements

> First Tracks Biotherapeutics, Inc. reported $170.5M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/TRAX
- Markdown: https://convexityos.com/fundamentals/TRAX.md
- SEC CIK: 0002091349
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:22 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002091349&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $155.6M | Total debt: $3.77M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $23.85M | $25.64M | $33.95M | $33.32M | $39.27M | $41.47M |
| Total Operating Expenses | $32.84M | $34.94M | $52.81M | $45.06M | $45.90M | $51.28M |
| **Operating Income** | -$32.84M | -$34.94M | -$52.81M | -$45.06M | -$45.90M | -$51.28M |
| **EBITDA** | -$32.75M | -$34.83M | -$52.69M | -$44.92M | -$45.76M | -$51.13M |
| Interest Income | $1.50M | $1.56M | $2.33M | $3.20M | $3.47M | $4.09M |
| **Net Income** | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M | -$47.20M |
| Basic EPS | -$0.88 | -$0.95 | -- | -$1.50 | -$1.47 | -- |
| **Diluted EPS** | -$0.88 | -$0.95 | -- | -$1.50 | -$1.47 | -- |
| Basic Shares Outstanding | 35.7M | 35.0M | -- | 27.8M | 28.8M | -- |
| Diluted Shares Outstanding | 35.7M | 35.0M | -- | 27.8M | 28.8M | -- |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $155.6M | $168.0M | $248.5M | $238.2M |
| Short-Term Investments | $0 | $0 | $37.99M | $73.44M |
| **Cash & Short-Term Investments** | $155.6M | $168.0M | $286.5M | $311.6M |
| Other Current Assets | $2.01M | $2.18M | -- | $1.88M |
| **Total Current Assets** | $165.7M | $177.7M | $289.4M | $316.4M |
| Property, Plant & Equipment, Net | $979K | $1.07M | $1.17M | $1.37M |
| Other Non-Current Assets | $0 | $0 | $0 | $256K |
| **Total Non-Current Assets** | $4.73M | $5.39M | $1.17M | $14.14M |
| **Total Assets** | $170.5M | $183.1M | $290.6M | $330.5M |
| Accounts Payable | $3.95M | $2.55M | $7.50M | $3.11M |
| **Total Current Liabilities** | $18.09M | $12.45M | $33.11M | $31.02M |
| **Total Non-Current Liabilities** | $1.35M | $1.90M | $0 | $12.03M |
| **Total Liabilities** | $19.45M | $14.34M | $33.11M | $43.05M |
| **Total Debt (incl. Leases)** | $3.77M | $4.33M | -- | $14.11M |
| Common Stock | $36K | $35K | -- | $0 |
| Retained Earnings | -$55.93M | -$24.58M | -- | $0 |
| Accumulated Other Comp. Income | $0 | $0 | -$146K | -$24K |
| **Total Stockholders' Equity** | $151.0M | $168.8M | $257.5M | $287.5M |
| Total Equity | $151.0M | $168.8M | $257.5M | $287.5M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M | -$47.20M |
| Depreciation & Amortization | $92K | $105K | $125K | $140K | $142K | $146K |
| Stock-Based Compensation | $8.90M | $8.32M | $11.50M | $9.85M | $7.66M | $7.75M |
| **Operating Cash Flow** | -$17.05M | -$31.92M | -$32.56M | -$30.69M | -$38.64M | -$45.01M |
| Capital Expenditure | $0 | -$25K | -$17K | -$12K | -$39K | -$35K |
| **Free Cash Flow** | -$17.05M | -$31.94M | -$32.58M | -$30.70M | -$38.68M | -$45.04M |
| Purchases of Investments | $0 | $0 | $0 | -$19.66M | -$54.21M | -$122.5M |
| **Investing Cash Flow** | $0 | -$25K | $34.98M | $103.3M | $36.40M | $14.85M |
| **Financing Cash Flow** | $4.66M | -$48.51M | $7.85M | -$7.06M | -$52.10M | $5.72M |
| **Net Change in Cash** | -$12.39M | -$80.45M | $10.27M | $65.53M | -$54.34M | -$24.44M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 9.16x | 14.28x | 8.74x | -- | -- | -- |
| Quick Ratio | 8.60x | 13.50x | 8.65x | -- | -- | -- |
| Debt to Equity | 0.02x | 0.03x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
